Abstract. Asparaginase like 1 (ASRGL1) protein belongs to the N-terminal nucleophile group, cleaving the isoaspartyl-dipeptides and L-asparagine by adding water. It tends to be overexpressed in cancerous tumors including ovarian cancer and breast tumors. The present study assessed the potential ability of ASRGL1 as a molecular target in gene-based cervical cancer treatment. The protein expression level of ASRGL1 was determined in paraffin-embedded tumor specimen by immunohistochemistry. Additionally, in order to assess the activity of ASRGL1 during the process of cervical cancer cell multiplication, ASRGL1-short hairpin (sh) RNA-expressing lentivirus was established, which was used to infect SiHa cells. The Cellomics ArrayScan VT1 Reader identified the influence of downregulation on SiHa caused by RNA interference-intervened ASRGL1. Flow cytometric analysis was also performed to evaluate the influence. The cyclin dependent kinase (CDK2), cyclin A2, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) expression levels were assessed by western blot analysis. ASRGL1 was observed to be overexpressed in cervical cancer tissues when compared with the adjacent normal tissues. The knockdown of ASRGL1 in SiHa by ASRGL1-shRNA lentivirus infection significantly inhibited cell growth and enhanced cellular apoptosis; the cells were also captured during the S phase. The knockdown of ASRGL1 expression led to the increased expression of Bax and decreased expression of Bcl-2, CDK2 and cyclin A2. In conclusion, ASRGL1 was closely associated with growth and apoptosis in cervical cancer. Therefore, ASRGL1 may be a novel, potentially effective anti-cervical cancer therapy.
Introduction
Cervical cancer is one of the most common destructive tumors of obstetrics and gynecology, severely endangering the health of women; however, an effective method for gene therapy is yet lacking (1, 2) . Despite that the advanced surgery and chemotherapy can enhance the therapeutic effect, there is still a high death rate owing to the recurrence of the disease in patients as well as drug resistance in chemotherapy (3, 4) . Vaccines cannot treat or protect all types of cancer patients or human papillomavirus (HPV) infection (5, 6) . The occurrence of cervical cancer is a complex, multifaceted process; a hazardous HPV infection has been recognized as the crucial factor for cervical cancer (7) (8) (9) . In China, ~62,000 new cervical cancer cases are identified, and ~28,000 women are deceased each year (10) . Therefore, the development of advanced medical therapy against the disease is of vital significance.
Asparaginase like 1 (ASRGL1) also termed as CRASH, is an enzyme that hydrolyzes asparagine or glutamine into aspartic acid and glutamic acid (11) ; it has been used to treat acute lymphoblastic leukemia (ALL) for decades (12) (13) (14) . However, the role of ASRGL1 in gynecological tumors has a different perspective. Studies on endometrial cancer found that ASRGL1 destitution is related to aggressive disease and meager survival (15, 16) . On the contrary, a high level of ASRGL1 was identified in mammary and ovarian cancers (17, 18) . Furthermore, there is no report about ASRGL1 expression and function in cervical cancer to date.
In this study, a high expression of ASRGL1 is shown to be present in cervical cancer tissue samples. Then, ASRGL1-short hairpin (sh) RNA-expressing lentivirus was adopted to explore the influence of ASRGL1 knockdown on human cervical cancer SiHa cells in vitro. ; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 mg/ml streptomycin, and 100 U/ml penicillin (Sangon Co., Ltd, Shanghai, China) at 37˚C in a humidified incubator with 5% CO 2 .
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Immunohistochemistry. Tissues were fixed in formalin and embedded in paraffin wax. The paraffin-embedded samples were cut into 4-mm-thick, then were deparaffinized and rehydrated in xylene and serially diluted alcohol solutions. Slides were heated by microwaving in 0.01 M sodium citrate solution for 15 min to retrieve antigen. Subsequently, the slides were incubated with ASRGL1 rabbit polyclonal antibody (1:100; Abcam, Cambridge, UK) at 4˚C overnight. Then, each slice was incubated with second antibody for 30 min. Finally, all slides were stained with diaminobenzidine followed by the hematoxylin was applied to counterstain. As a negative control (NC), the primary antibody was replaced with PBS. All the images were analyzed by conventional optical microscopy.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The cellular RNA from SiHa cells was extracted by TRIzol (Invitrogen, Shanghai, China). Subsequently, 2 µg mRNA was reverse transcribed into cDNA. The primers were designed as follows: ASRGL1 forward, 5'-CGA GTT CAA CGC AGG TTG TG-3' and reverse, 5'-GGG ATT TGC TAT ACA CTG GAC TG-3'; GAPDH forward, 5'-TGA CTT CAA CAG CGA CAC CCA-3' and 5'-CAC CCT GTT GCT GTA GCC AAA-3'. qPCR was performed using the SYBR-Green kit (Takara Biotechnology Co., Ltd., Dalian, China) and the ABI 7500 Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Relative expression as determined using the 2 -∆∆Cq method as described previously (19) . The RT-qPCR reaction was as follows: 95˚C for a period of 15 sec, followed by 45 cycles including denaturation at 95˚C for 5 sec, annealing at 45-62˚C for 30 sec. The PCR amplification of GAPDH and ASRGL1 provided an amplicon of 121 and 127 bp, respectively.
Recombinant lentiviral vector production and cell infection.
GeneChem Co., Ltd. (Shanghai, China) made the blueprint of the mutually complementary DNA sequence (5'-CAG TCC AGT GTA TAG CAA A-3') of ASRGL1. The knockdown efficiencies of these oligonucleotides were tested by incorporating into the lentivirus-based psc14173 (GeneChem Co., Ltd.) via AgeI/EcoRI sites. The lentivirus particles functioned as described previously (20) . With respect to the lentivirus infection, SiHa cells were seeded in 6-well plates. Then, ASRGL1-shRNA-lentivirus or NC lentivirus was added according to the multiplicity of infection (MOI). The cells were examined using fluorescence microscope (Olympus, Tokyo, Japan) after three days.
Western blot analysis. After several washes with cold phosphate-buffered saline (PBS), the cells were solubilized in precooled 2X lysis buffer (100 mM Tris, pH 6.8, 10% glycerol, 4% SDS, 2% 2-ME, 10 mM EDTA) for 30 min on ice. Then, the supernatants were collected after the lysates were centrifuged at 14,000 x g, 4˚C for 10 min. An equivalent amount of protein is separated by 12% SDS-PAGE and transferred on PVDF membrane (Millipore, Bedford, MA). Then, the membrane was blocked in 5% fat-free milk, in TBST buffer, followed by probing with the anti-ASRGL1 (1:1,000), Bcl-2-associated X protein (anti-Bax; 1:1,000), anti-B-cell lymphoma 2 (Bcl-2; 1:1,000), anti-cyclin dependent kinase (CDK2; 1:1,000), anti-cyclin A2 (1:1,000; all Abcam) antibodies at 4˚C overnight. GAPDH (1:2,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) is an endogenous control. After 3 washes in TBST, the membrane was incubated with the HRP-conjugated goat anti-mouse and goat anti-rabbit secondary antibody (1:5,000; Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. Finally, it was detected using ECL reagent (ECL-Plus kit; Amersham, Piscataway, NJ, USA).
Cell proliferation experiment. SiHa cells in the logarithmic stage were digested and resuspended; 2,000 cells/well were seeded into 96-well plates. Each experiment was performed three times independently. Since day 2, Cellomics ArrayScan VT1 Readers (Cellomics, Inc., Pittsburgh, PA, USA) calculated the cell number once a day at an interval of five days. By adjusting the analysis settings of input parameters, the number of cells with green fluorescence in each scan orifice were calculated accurately. Finally, the cell proliferation curve was plotted.
Analysis of cell cycle. Cells were infected with ASRGL1 shRNA lentivirus or control and were cultured to 80% confluency. Subsequently, the cells were digested, resuspended, and centrifuged at 1,300 rpm for 5 min, washed in chilled PBS, and fixed in 75% alcohol for 1 h, followed by staining with propidium iodide (PI; 50 µg/ml, Sigma-Aldrich ® , St. Louis, MO, USA) in the presence of RNase A (100 µg/ml; Fermentas ® , Shanghai, China). The cell cycle was analyzed using BD FACSCalibur flow cytometer (FCM; BD Biosciences, San Diego, CA, USA).
Apoptotic assay. Cells were seeded into 6-well plates and transfected with ASRGL1-shRNA or NC lentivirus for 72 h. Then, the cells were digested, resuspended, centrifuged at 1,300 rpm for 5 min, washed in cold PBS and 1X binding buffer, followed by resuspension in 1 ml 1X staining buffer, and 5 ml Annexin V-APC (eBioscience, San Diego, CA, USA) into 100 ml cell suspension. The reaction was incubated in the dark for 15 min. The cells were analyzed by FCM.
Data analysis. The cell cultures were analyzed in triplicate using the SPSS version 21.0 software (IBM SPSS, Corp., Armonk, NY, USA). The original data were presented as mean ± standard deviation (SD). The discrepancies in ASRGL1 knockdown and control cells were comparison using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of ASRGL1 in clinical cervical carcinoma tissues.
The ASRGL1 proteins were mainly located in the cytoplasm and was found to be overexpressed in cervical tissues from patients with cervical cancer when compared with the paracancerous tissue specimens, as analyzed by immunohistochemistry ( Fig. 1) (P<0.05) .
Knockdown efficiency of ASRGL1. The efficiency of ASRGL1 in SiHa cervical cancer cells was examined by infecting the cells with ASRGL1 shRNA lentivirus and NC shRNA lentivirus-expressing GFP, respectively. Then, we examined the fluorescence level of GFP protein to determine the infection efficiency. As seen in Fig. 2A , 72 h after infection, >80% cells were expressing GFP as assessed by f luorescence microscopy. The mRNA and protein expression level of ASRGL1 after shRNA infection was evaluated by quantitative PCR and western blot analysis, respectively. As observed in Fig. 2B , the ASRGL1 mRNA level was decreased by almost 90% in cell lines infected with ASRGL1 shRNA lentivirus as compared to the NC group. Furthermore, Fig. 2C showed the downregulation of ASRGL1 protein expression in SiHa cells infected with ASRGL1 shRNA lentivirus. Fig. 2D , the quantitative analysis of western blotting brands.
Knockdown of ASRGL1 in SiHa cells inhibits cell multiplication.
In order to evaluate the function of ASRGL1 in the proliferation of cervical cancer cells, GFP-expressing cells were infected with ASRGL1 shRNA lentivirus and NC shRNA lentivirus, respectively using Cellomics ArrayScan VT1 Readers continuously for 5 days. As shown in Fig. 3A , the cells transfected with NC shRNA lentivirus were significantly more as compared to the ASRGL1-shRNA-transfected cells on day 5 (P<0.05). Fig. 3B further confirmed that knockdown of ASRGL1 had a dramatic impact on curbing the SiHa cells' number.
Effect of ASRGL1 shRNA on cell cycle. FCM was used to analyze whether the knockdown of ASRGL1 will affect the cell cycle progression in SiHa cells. As illustrated in Fig. 4A , the ASRGL1-shRNA-transfected cells were distributed in G1 phase (37.71±0.86%, P<0.01); S phase (51.95±0.68%, P<0.01), and G2/M (10.34±1.31%, P<0.01). However, the NC-shRNA-transfected cells were distributed in G1 phase (66.62±0.27%, P<0.01); S phase (15.30±0.26%, P<0.01), and G2/M (18.08±0.19%, P<0.01). Furthermore, the ratios of S stage cells in ASRGL1-shRNA transfected group were significantly larger than those in the negative shRNA control group (P<0.01). Additionally, the levels of CDK2 and cyclin A2 were significantly reduced in the ASRGL1 siRNA-transfected cells (Fig. 4B) . Cyclin A2 appeared in the late Go, can combine with CDK2 and promote the synthesis of DNA in S phase. Consequently, the knockdown of ASRGL1 might capture the cell cycle during the S stage in SiHa cells.
Knockdown of ASRGL1 in SiHa cells increases cellular apoptosis.
FCM was employed to analyze whether the knockdown of ASRGL1 affected the cell apoptosis in SiHa cells (Fig. 5A) . The rate of apoptosis in the ASRGL1-shRNA exhibited a dramatic increase as compared to the negative shRNA control group (ASRGL1-shRNA 11.483±0.55% vs. NC-shRNA 4.36±0.15%, P<0.05). Hence, silencing the expression of ASRGL1 in SiHa cells induces apoptosis. Subsequently, we measured the expression level of cell apoptosis-associated proteins Bax and Bcl-2 after the knockdown of ASRGL1 (Fig. 5B) . The proapoptotic protein, Bax, was significantly enhanced, whereas the expression of anti-apoptosis Bcl-2 protein was reduced compared with the control. 
Discussion
During the present study, the ASRGL1 expression was significantly upregulated in cervical cancer tissue compared with the paracancerous tissue. To explore the function of ASRGL1 in SiHa cells, we used ASRGL1 shRNA lentivirus to inhibit the expression of ASRGL1, which indicated that the loss of ASRGL1 could significantly suppress the proliferation and promote apoptosis in SiHa cells. However, converse results were observed in endometrial carcinoma (16) , but similar in mammary and ovarian cancers (17, 18) . This phenomenon suggested that ASRGL1 was closely associated with the tumor growth and can function as the potential target of cervical cancer gene therapy. There is a striking discrepancy between the expression of ASGRL1 on mRNA and on protein level after lentivirus. This is because the main role of shRNA is in RNA level, and there is also a process of RNA transcription before protein transcription, so the RNA level effect is more obvious. The expression level of cell proapoptotic proteins Bax exhibited a dramatic increase as compared to the negative shRNA control group, indicate that the ASRGL1 may acts as an anti-apoptotic factor in the cell apoptotic process. Moreover, after infection with ASRGL1 shRNA lentivirus, the ratio of cells in G1 and G2/M stages were declined significantly; however, that in the S stage was elevated significantly. The cell cycle related proteins Cyclin A2 and CDK2 are the important proteins that promote cells to transform from S phase to G2 phase and contribute the synthesis of DNA (21, 22) . In this study, the results of western blot analysis show a decline in both CDK2 and Cyclin A2 protein expression compared with the control. This phenomenon indicated that ASRGL1 could inhibit tumor growth by regulating the cell cycle. Thus, the specific molecular mechanism underlying the ASRGL1-regulated cervical cancer cell growth necessitates further investigations in other cervical tumor cell lines.
Owing to the rapid advances in tumor molecular biology and genetic engineering, the genetic treatment is rendered as a cutting-edge therapy mode for tumors (23) . RNA interference-based gene therapy can accurately and effectively silence the expression of the target gene. Therefore, identifying the novel biomarker for cervical cancer intervention is essential. The gene encoding ASRGL1, one part of the N-terminal nucleophile (Ntn) hydrolase group (24) , occurs in duplicate, and the corresponding transcriptional activation was assessed in endometrial and breast cancers (16, 18) . As the final step in the degradation of cell surface glycoproteins, ASRGL1 can remove the carbohydrate side chains from asparagine (25) , thereby controlling the signaling function from the cell surface, metabolism of tumor cells, and cell growth (11) . However, the role t in cervical cancer has not yet been reported. In the current study, the knockdown of ASRGL1 in SiHa cells by ASRGL1-shRNA lentivirus can significantly inhibit cell growth and enhance cellular apoptosis.
In conclusion, ASRGL1 had a close relationship with growth and apoptosis in cervical cancer. The knockdown of ASRGL1 can significantly inhibit the proliferation, promote apoptosis, and arrest the cells in S phase. Thus, it is a potential method to treat cervical cancer by downregulating ASRGL1 in these overexpressed cells.
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